Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 2Withdrawn 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Pancreatic Neoplasms 5Recurrence 2Neoplasms 2Carcinoma, Merkel Cell 2Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Pharmacokinetics 1Ovarian Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Squamous Cell 1Breast Neoplasms 1Advanced Triple Negative Breast Cancer 1

Interventions

pembrolizumab 8avelumab 6fludarabine 3Radiotherapy 3Radiation 3Cyclophosphamide 3cemiplimab 2atezolizumab 2aldesleukin 2Interleukin-2 2Interferon-beta 2ALT-803 2talimogene laherparepvec 1poly ICLC 1pentetreotide 1interferon gamma-1b 1epacadostat 1efineptakin alfa 1durvalumab 1cabozantinib 1bempegaldesleukin 1TTI-621 1Paclitaxel 1Nivolumab 1Interferon-gamma 1Influenza Vaccines 1Immunotherapy 1High-Intensity Focused Ultrasound Ablation 1Carboxylesterase 1B7-H1 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Carcinoma, Merkel Cell × ALT-803 × Clear all
NCT03853317 2024-08-09

QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint Therapy

ImmunityBio, Inc.

Phase 2 Terminated
9 enrolled 13 charts
Dermatologic

Carcinoma, Merkel Cell

NCT02465957 2024-05-02

QUILT-3.009: Patients With Stage III (IIIB) or Stage (IV) Merkel Cell Carcinoma (MCC)

ImmunityBio, Inc.

Phase 2 Terminated
7 enrolled 11 charts
Dermatologic

Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡